Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 37,185	$ 36,632
Short-term investments – available for sale	339,056	118,853
Prepaid clinical trial and preclinical study costs	4,389	8,144
Prepaid expenses and other current assets	670	3,411
Total current assets	381,300	167,040
Right-of-use assets	1,200	1,418
Deferred financing costs	130	38
Deposits	33	33
Total assets	382,663	168,529
Current liabilities:
Accounts payable	5,711	8,529
Other accrued liabilities	7,375	13,114
Lease liability, current	319	304
Total current liabilities	13,405	21,947
Lease liability, net of current portion	1,018	1,260
Total long-term liabilities	1,018	1,260
Total liabilities	14,423	23,207
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at September 30, 2023 and December 31, 2022; no shares issued and outstanding at September 30, 2023 and December 31, 2022
Common stock, $0.00001 par value: 300,000,000 shares authorized at September 30, 2023 and December 31, 2022; 100,028,828 shares issued and outstanding at September 30, 2023 and 78,257,258 shares issued and outstanding at December 31, 2022	1	1
Treasury stock at cost, 2,193,251 shares at September 30, 2023 and December 31, 2022	(6,795)	(6,795)
Additional paid-in capital	729,278	445,267
Accumulated deficit	(353,339)	(292,049)
Accumulated other comprehensive loss	(905)	(1,102)
Total stockholders’ equity	368,240	145,322
Total liabilities and stockholders’ equity	$ 382,663	$ 168,529